Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

The bHLH network underlying plant shade-avoidance.

Buti S, Hayes S, Pierik R.

Physiol Plant. 2020 Feb 13. doi: 10.1111/ppl.13074. [Epub ahead of print]

PMID:
32053251
2.

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.

Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M.

Sci Rep. 2020 Feb 5;10(1):2304. doi: 10.1038/s41598-020-59358-9.

3.

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C.

Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020.

4.

Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis.

Buti S, Petrelli F, Ghidini A, Vavassori I, Maestroni U, Bersanelli M.

Clin Transl Oncol. 2020 Jan 19. doi: 10.1007/s12094-020-02292-z. [Epub ahead of print]

PMID:
31956940
5.

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study.

Bersanelli M, Lattanzi E, D'Abbiero N, Buti S, Leonetti A, Canè MG, Trapani S, Gravina G, Porzio G, Cannita K, Marino PD, Grassadonia A, Tinari N, Tursi M, Giaiacopi E, Michiara M, Bordi P, Perrone F, Caravatta L, Trignani M, Genovesi D, Natoli C, Ficorella C, Tiseo M, Cortellini A.

Biomed Rep. 2020 Feb;12(2):59-67. doi: 10.3892/br.2019.1265. Epub 2019 Dec 13.

6.

A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

Bersanelli M, Buti S, Ghidini A, Tiseo M, Petrelli F.

Anticancer Drugs. 2020 Mar;31(3):211-215. doi: 10.1097/CAD.0000000000000883.

PMID:
31917698
7.

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab.

Bersanelli M, Gnetti L, Vaglio A, Sverzellati N, Campanini N, Incerti M, Galetti M, Varotti E, Corrado M, Parziale R, Bottarelli L, Azzoni C, Silini EM, Leonardi F, Buti S.

Acta Biomed. 2019 Dec 23;90(4):468-474. doi: 10.23750/abm.v90i4.7057.

PMID:
31910171
8.

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N.

Cancers (Basel). 2019 Dec 30;12(1). pii: E84. doi: 10.3390/cancers12010084.

9.

Unlocking the secret of the obesity paradox in renal tumours.

Santoni M, Cortellini A, Buti S.

Lancet Oncol. 2020 Feb;21(2):194-196. doi: 10.1016/S1470-2045(19)30783-1. Epub 2019 Dec 20. No abstract available.

PMID:
31870810
10.

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.

Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R.

Expert Rev Cardiovasc Ther. 2019 Dec;17(12):917-927. doi: 10.1080/14779072.2019.1704626. Epub 2019 Dec 19.

PMID:
31829045
11.

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.

Cortellini A, Buti S, Agostinelli V, Bersanelli M.

Semin Oncol. 2019 Aug - Oct;46(4-5):362-371. doi: 10.1053/j.seminoncol.2019.10.003. Epub 2019 Nov 7.

PMID:
31727344
12.

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.

Buti S, Bersanelli M, Viansone A, Leonetti A, Masini C, Ratta R, Procopio G, Maines F, Iacovelli R, Ciccarese C, Vitale MG, De Giorgi U, Mucciarini C, Maruzzo M, Prati G, Lattanzi E, Ciammella P, Bruni A, Andreani S, D'Abbiero N.

Cancer Treat Res Commun. 2020;22:100161. doi: 10.1016/j.ctarc.2019.100161. Epub 2019 Sep 29.

13.

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

Bersanelli M, Cortellini A, Buti S.

Ann Transl Med. 2019 Sep;7(Suppl 6):S190. doi: 10.21037/atm.2019.07.37. No abstract available.

14.

Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.

Rebuzzi SE, Perrone F, Bersanelli M, Bregni G, Milella M, Buti S.

Expert Rev Mol Diagn. 2020 Feb;20(2):169-185. doi: 10.1080/14737159.2019.1680286. Epub 2019 Oct 24.

PMID:
31608727
15.

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches".

Buti S, Leonetti A, Lattanzi E, D'Abbiero N, Bersanelli M.

Ann Transl Med. 2019 Jul;7(Suppl 3):S106. doi: 10.21037/atm.2019.05.04. No abstract available.

16.

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.

Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M.

Sci Rep. 2019 Sep 13;9(1):13218. doi: 10.1038/s41598-019-49250-6. Erratum in: Sci Rep. 2020 Feb 5;10(1):2304.

17.

Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.

Vitale MG, Baldessari C, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerma K, Cascinu S, Sabbatini R.

Clin Genitourin Cancer. 2019 Oct;17(5):e903-e908. doi: 10.1016/j.clgc.2019.06.009. Epub 2019 Jul 8. No abstract available.

PMID:
31375351
18.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
19.

Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review.

Trapani S, Manicone M, Sikokis A, D'Abbiero N, Salaroli F, Ceccon G, Buti S.

Crit Rev Oncol Hematol. 2019 Oct;142:9-15. doi: 10.1016/j.critrevonc.2019.07.006. Epub 2019 Jul 11.

PMID:
31325712
20.

Organ-specific phytohormone synthesis in two Geranium species with antithetical responses to far-red light enrichment.

Gommers CMM, Buti S, Tarkowská D, Pěnčík A, Banda JP, Arricastres V, Pierik R.

Plant Direct. 2018 Aug 21;2(8):e00066. doi: 10.1002/pld3.66. eCollection 2018 Aug.

21.

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.

Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group.

Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.

22.

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

Peverelli G, Raimondi A, Ratta R, Verzoni E, Bregni M, Cortesi E, Cartenì G, Fornarini G, Facchini G, Buti S, Galli L, Tucci M, Prisciandaro M, Procopio G.

Clin Genitourin Cancer. 2019 Aug;17(4):291-298. doi: 10.1016/j.clgc.2019.05.002. Epub 2019 May 13.

PMID:
31178240
23.

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Pignata S, Banna GL.

Crit Rev Oncol Hematol. 2019 Jul;139:87-90. doi: 10.1016/j.critrevonc.2019.05.003. Epub 2019 May 8. Review.

PMID:
31112887
24.

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes.

Bersanelli M, Santoni M, Ticinesi A, Buti S.

Target Oncol. 2019 Jun;14(3):247-252. doi: 10.1007/s11523-019-00643-7.

PMID:
31073691
25.

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions.

Bersanelli M, Buti S, Santoni M, Ziglioli F, Maestroni U.

Ann Transl Med. 2019 Mar;7(Suppl 1):S54. doi: 10.21037/atm.2019.03.06. No abstract available.

26.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M.

Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.

PMID:
31027702
27.

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN.

Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9.

PMID:
30967420
28.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

29.

The effect of a treatment delay on outcome in metastatic renal cell carcinoma.

Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G.

Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

PMID:
30935843
30.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21.

PMID:
30885550
31.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

32.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Oncologist. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22.

33.

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.

Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, Rusca M, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Cortellini A, Rapacchi E, Caruso G, Silini EM, Maestroni U, Buti S.

Immunotherapy. 2019 Jan;11(1):21-35. doi: 10.2217/imt-2018-0097. Erratum in: Immunotherapy. 2019 Feb;11(3):255.

34.

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.

Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M, Buti S, Bordi P, Aversa F, Ardizzoni A, Quaini F, Tiseo M.

Lung Cancer. 2019 Jan;127:153-163. doi: 10.1016/j.lungcan.2018.11.038. Epub 2018 Nov 29.

PMID:
30642544
35.

[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Banna GL.

Recenti Prog Med. 2018 Nov;109(11):540-546. doi: 10.1701/3031.30291. Review. Italian.

PMID:
30565573
36.

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Cortellini A, Bersanelli M, Ficorella C, Buti S.

Thorac Cancer. 2019 Feb;10(2):401. doi: 10.1111/1759-7714.12926. Epub 2018 Dec 8. No abstract available.

37.

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

Santoni M, Conti A, Buti S, Bersanelli M, Foghini L, Piva F, Giulietti M, Lusuardi L, Battelli N.

Immunotherapy. 2018 Nov;10(15):1303-1313. doi: 10.2217/imt-2018-0067.

PMID:
30474475
38.

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.

Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C.

Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

PMID:
30396828
39.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
40.

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date.

Bersanelli M, Leonardi F, Buti S.

Cancer Manag Res. 2018 Sep 21;10:3773-3780. doi: 10.2147/CMAR.S160485. eCollection 2018. Review.

41.

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.

Santoni M, Piva F, De Giorgi U, Mosca A, Basso U, Santini D, Buti S, Lolli C, Terrone C, Maruzzo M, Iuliani M, Bersanelli M, Conti A, Mazzucchelli R, Montironi R, Burattini L, Berardi R.

Anticancer Res. 2018 Oct;38(10):5773-5782. doi: 10.21873/anticanres.12916.

PMID:
30275199
42.

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.

Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M.

Drug Des Devel Ther. 2018 Sep 10;12:2857-2873. doi: 10.2147/DDDT.S124380. eCollection 2018. Review.

43.

Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.

Rebuzzi SE, Bregni G, Grassi M, Damiani A, Buscaglia M, Buti S, Fornarini G.

Immunotherapy. 2018 Sep;10(13):1123-1132. doi: 10.2217/imt-2018-0042. Review.

PMID:
30236027
44.

Patient performance status and cancer immunotherapy efficacy: a meta-analysis.

Bersanelli M, Brighenti M, Buti S, Barni S, Petrelli F.

Med Oncol. 2018 Aug 20;35(10):132. doi: 10.1007/s12032-018-1194-4. Review.

PMID:
30128793
45.

Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series.

Leonetti A, D'Abbiero N, Baldari G, Andreani S, Ruffini L, Viansone AA, Buti S.

Int J Urol. 2018 Oct;25(10):879-886. doi: 10.1111/iju.13773. Epub 2018 Aug 13.

46.

Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present).

Leonetti A, Zielli T, Buti S.

Future Oncol. 2018 Sep;14(22):2223-2224. doi: 10.2217/fon-2018-0304. Epub 2018 Aug 1. No abstract available.

47.

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab.

Bersanelli M, Gnetti L, Azzoni C, Bottarelli L, Sverzellati N, Campanini N, Varotti E, Corrado M, Parziale R, Rapacchi E, Caruso G, Leonardi F, Silini EM, Buti S.

Immunotherapy. 2018 Jul;10(9):743-752. doi: 10.2217/imt-2017-0160. Erratum in: Immunotherapy. 2018 Oct;10(14):1287-1288.

PMID:
30008256
48.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

49.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M.

Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175.

PMID:
29882691
50.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246

Supplemental Content

Support Center